Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2002

View Archived Issues

Amsalog well tolerated at oral doses up to 1600 mg/m2 in cancer patients

Pantoprazole safely eliminates gastrointestinal bleeding in patient with short bowel syndrome

Barr to acquire Enhance assets and liabilities

Genome Therapeutics updates achievements in 2001

NX-1207 shows efficacy in preclinical studies for treatment of benign prostatic hyperplasia

Ivax completes pilot phase II study of E2CDS in postmenopausal women

Novel antibiotic for acne enters phase I testing

Phase II trial for ISIS-14803 in hepatitis C commences

Array BioPharma and Japan Tobacco to develop small-molecule therapeutics

Licensing opportunity from NIH: use of CpG oligodeoxynucleotides to promote angiogenesis

PTH2 receptors for treatment of chronic pain available for licensing from NIH

rNAPc2 safe and effective in phase IIa trial in patients undergoing PCI

Cognitive function improved by NS-2330 in normal subjects and those with possible AD

Nonopiate analgesic provides significant and rapid dental pain relief after intranasal dosing

AHP changes name to Wyeth

Roche's MabThera and Xeloda cleared for new indications in Europe

Potent marine neurotoxin advances towards clinical trials in pain and opiate withdrawal

NeuroSearch and Ferrer discontinue development of NS-2710 for treatment of anxiety

Novel cancer therapy now available in U.S.

Novel antitussive agents in the Dompe pipeline

Virocell designs new vanadium compounds which potentiate effects of anti-HIV agents

Selective small-molecule inhibitors of ErbB-2 kinase discovered at Georgetown

Antitumor lipid-peptide conjugates claimed by Indian research group

Inhibitors of iNOS claimed by AstraZeneca for inflammatory disorders and pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 11, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...